OBJECTIVES: Non-compliance to eye drops for treating glaucoma is a major concern as it may lead to serious complications. A subconjunctivally injected solution, which is a new method of delivering glaucoma medicine, replaces the daily use of eye drops via a slow release mechanism. The injected solution can last several months and may be attractive to patients for its convenience. The objective of this study is to predict stated demand for a new injectable solution for delivering glaucoma medicine based on product features, patient characteristics and physician recommendation. METHODS: A web-enabled discrete-choice experiment (DCE) survey was administered to 500 glaucoma patients in the US who are part of an internet panel. Patients were asked to choose between an injectable solution and eye drops in a series of questions. The injectable solution was defined in terms of frequency of administration, out-of-pocket cost, percentage of patients who have adopted the new technology and doctor’s recommendation.   RESULTS: The DCE survey results show that cost, frequency of administration, doctor recommendation and percentage of adaption of the technology among patients are all significant factors influencing patient preferences for a new injectable solution. However, patients are most sensitive to the out-of-pocket costs. About 9% are likely to be early adopters and will want the new technology even at fairly high prices, whereas 20% are unlikely to opt for the injectable solution at any price.  The remaining 71% may opt for the injectable solution, depending on the price. Patient age was negatively and household income was positively correlated with uptake. CONCLUSIONS:  The demand for the injectable solution is likely to be roughly 15% in the early stages of market entry, but will increase over time to 30% or higher as more physicians begin to recommend the injectable solution to their patients, assuming it continues to have a strong safety and efficacy profile.